5 results
The primary objective of this study is to assess the renal safety of CSL112 in subjects with moderate RI and AMI after administration of up to 4 weekly infusions of CSL112.The secondary objectives of the study are:1. To further characterize the…
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics and activity of ACP-196 in treating subjects with Waldenström disease.
The purpose of this study is to evaluate the efficacy, activity, safety, pharmacodynamics and pharmacokinetics of ACP-196 in treating subjects with Mantle Cell Lymphoma (MCL)
Primary ObjectivesPhase 1bConfirm the recommended CyPep-1 dose 20 mg every two weeks (Q2W) when administered by intratumoral (IT) injection in combination with pembrolizumab Phase 2aAssess the anti-tumor activity of CyPep-1 administered by IT…
Therapy:The investigational product, ACP-196, will be supplied as hardgelatin capsules for oral administration.Commercially available ibrutinib (IMBRUVICA®) will be used asthe reference therapy.Objectives: Primary Objective:To assess whether ACP-196…